NCT03055494 - Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

April 25, 2018

Study Completion Date

February 26, 2019

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

Secukinumab

Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48

BIOLOGICAL

Placebo

Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48

Trial Locations (15)

10065

Novartis Investigative Site, New York

14203

Novartis Investigative Site, Buffalo

23507

Novartis Investigative Site, Norfolk

30342

Novartis Investigative Site, Atlanta

46256

Novartis Investigative Site, Indianapolis

71913

Novartis Investigative Site, Hot Springs

77004

Novartis Investigative Site, Webster

84107

Novartis Investigative Site, Murray

90033

Novartis Investigative Site, Los Angeles

92701

Novartis Investigative Site, Santa Ana

97223

Novartis Investigative Site, Portland

08520

Novartis Investigative Site, East Windsor

07052

Novartis Investigative Site, West Orange

10025 1737

Novartis Investigative Site, New York

15213-3403

Novartis Investigative Site, Pittsburgh